Tiziana Life Sciences Ltd. Announces Annual Report Filed to Regain Nasdaq Compliance
Tiziana Life Sciences (Nasdaq: TLSA) announced the filing of its Annual Report on Form 20-F for the year ended December 31, 2021, on May 23, 2022. Following this filing, the company confirmed it has regained compliance with Nasdaq Listing Rules. Tiziana is focused on developing innovative immunotherapy delivery methods, including intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody, and milciclib, a pan-CDK inhibitor. The company’s alternative drug delivery technologies aim to enhance efficacy, safety, and tolerability.
- Filed Annual Report on Form 20-F, confirming regained compliance with Nasdaq Listing Rules.
- Developing innovative drug delivery technologies with potential improvements in efficacy and safety.
- Lead candidates showing favorable safety profiles and clinical responses.
- None.
Form 20-F Filed on May 23, 2022 Following Receipt of Notice from Nasdaq Regarding Filing Deadline of its Annual Report
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of monoclonal antibody delivery, announced today that it filed its Annual Report on Form 20-F for the year ended December 31, 2021 (the “Annual Report”) on May 23. Subsequent to the filing, the Company confirms that it has regained compliance with Nasdaq Listing Rules.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral, and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
For further inquiries:
| Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager +44 (0) 207 495 2379 email: info@tizianalifesciences.com | |
Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com |
FAQ
What is Tiziana Life Sciences' stock symbol?
When did Tiziana Life Sciences file its Annual Report on Form 20-F?
What does Tiziana Life Sciences focus on?
What are Tiziana Life Sciences' lead drug candidates?
What was the outcome of Tiziana Life Sciences' filing with Nasdaq?
